JP2009515950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515950A5 JP2009515950A5 JP2008541108A JP2008541108A JP2009515950A5 JP 2009515950 A5 JP2009515950 A5 JP 2009515950A5 JP 2008541108 A JP2008541108 A JP 2008541108A JP 2008541108 A JP2008541108 A JP 2008541108A JP 2009515950 A5 JP2009515950 A5 JP 2009515950A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- heterocycloalkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 18
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- NRIKGKKUCXYEJU-UHFFFAOYSA-N 2-[[2-amino-6-[2-[3-(furan-2-yl)phenyl]ethyl]pyrimidin-4-yl]oxymethyl]benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C(OCC=2C(=CC=CC=2)C#N)=NC(N)=NC=1CCC(C=1)=CC=CC=1C1=CC=CO1 NRIKGKKUCXYEJU-UHFFFAOYSA-N 0.000 claims 1
- MAFVULDJJNEXRY-UHFFFAOYSA-N 4-(cyclohexylmethoxy)-6-[2-[3-(furan-2-yl)phenyl]ethyl]pyrimidin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C(OCC2CCCCC2)=NC(N)=NC=1CCC(C=1)=CC=CC=1C1=CC=CO1 MAFVULDJJNEXRY-UHFFFAOYSA-N 0.000 claims 1
- IINIAKJDSURVSA-UHFFFAOYSA-N 4-[2-(1,3-dioxan-2-yl)ethoxy]-6-[2-[3-(furan-2-yl)phenyl]ethyl]pyrimidin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C(OCCC2OCCCO2)=NC(N)=NC=1CCC(C=1)=CC=CC=1C1=CC=CO1 IINIAKJDSURVSA-UHFFFAOYSA-N 0.000 claims 1
- BQBVNXXFXITLBW-UHFFFAOYSA-N 4-[2-[3-(furan-2-yl)phenyl]ethyl]-6-(2-phenoxyethoxy)pyrimidin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C(OCCOC=2C=CC=CC=2)=NC(N)=NC=1CCC(C=1)=CC=CC=1C1=CC=CO1 BQBVNXXFXITLBW-UHFFFAOYSA-N 0.000 claims 1
- IWOOPXXHDKZCIE-UHFFFAOYSA-N 4-[2-[3-(furan-2-yl)phenyl]ethyl]-6-(3-methylbutoxy)pyrimidin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1=NC(OCCC(C)C)=CC(CCC=2C=C(C=CC=2)C=2OC=CC=2)=N1 IWOOPXXHDKZCIE-UHFFFAOYSA-N 0.000 claims 1
- JSSUYSWUQWCDFU-UHFFFAOYSA-N 4-chloro-6-[2-[3-(furan-2-yl)phenyl]ethyl]pyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(CCC=2C=C(C=CC=2)C=2OC=CC=2)=N1 JSSUYSWUQWCDFU-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- -1 cycloalk Le Chemical group 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73743505P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/001281 WO2007058581A1 (en) | 2005-11-15 | 2006-11-13 | Novel 2-aminopyrimidine derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515950A JP2009515950A (ja) | 2009-04-16 |
| JP2009515950A5 true JP2009515950A5 (enExample) | 2010-01-07 |
Family
ID=38048894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541108A Pending JP2009515950A (ja) | 2005-11-15 | 2006-11-13 | 新規な２−アミノピリミジン誘導体およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080255167A1 (enExample) |
| EP (1) | EP1951681A4 (enExample) |
| JP (1) | JP2009515950A (enExample) |
| CN (1) | CN101360722A (enExample) |
| WO (1) | WO2007058581A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| AR077277A1 (es) * | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
| EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| HUP0300029A2 (en) * | 2000-02-25 | 2003-05-28 | Hoffmann La Roche | Adenosine receptor modulators, pharmaceutical compositions containing them and their use |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| CN101084198A (zh) * | 2004-10-15 | 2007-12-05 | 阿斯利康(瑞典)有限公司 | 取代的氨基－嘧啶酮及其用途 |
| WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
| MX2007016182A (es) * | 2005-06-14 | 2008-03-07 | Schering Corp | Inhibidores de aspartil proteasas. |
| EP1902057B1 (en) * | 2005-06-14 | 2013-10-23 | Merck Sharp & Dohme Corp. | Macrocyclic heterocyclic aspartyl protease inhibitors |
| PE20070798A1 (es) * | 2005-10-31 | 2007-08-24 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
-
2006
- 2006-11-13 JP JP2008541108A patent/JP2009515950A/ja active Pending
- 2006-11-13 US US12/093,646 patent/US20080255167A1/en not_active Abandoned
- 2006-11-13 WO PCT/SE2006/001281 patent/WO2007058581A1/en not_active Ceased
- 2006-11-13 CN CNA2006800511227A patent/CN101360722A/zh active Pending
- 2006-11-13 EP EP06813004A patent/EP1951681A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515949A5 (enExample) | ||
| JP2014526549A5 (enExample) | ||
| JP2009520685A5 (enExample) | ||
| RU2497813C2 (ru) | 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение | |
| JP2007529486A5 (enExample) | ||
| JP2008516945A5 (enExample) | ||
| SI3074386T1 (en) | New aminopyrimidine derivatives | |
| JP2010510319A5 (enExample) | ||
| JP2005510473A5 (enExample) | ||
| JP2009515950A5 (enExample) | ||
| JP2017508763A5 (enExample) | ||
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2021500345A5 (enExample) | ||
| JP2004534010A5 (enExample) | ||
| JP2009541311A5 (enExample) | ||
| JP2014521623A5 (enExample) | ||
| JP2013510876A5 (enExample) | ||
| JP2018502877A5 (enExample) | ||
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| RU2016141088A (ru) | 5-замещённые индазол-3-карбоксамиды и их получение и применение | |
| JP2009510043A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| RU2009121564A (ru) | Азаадамантановые производные и способы применения | |
| JP2004536814A5 (enExample) |